Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The study intends on enrolling 48 subjects with diabetes. Diabetic subjects that no longer
need insulin will be randomly placed (like the flip of a coin) on a diabetes pill called
metformin, a diabetes pill called sitagliptin or a placebo pill (a pill without active
medication). Subjects on pills will be followed for 3½ years and undergo blood tests at
specified intervals to assess their ability to make insulin. These studies will allow a
better understanding of the factors that lead to high blood sugar in patients with
ketosis-prone diabetes mellitus (KPDM) and direct the best diabetes treatment for this
patient population.
Hypothesis: Metformin therapy or sitagliptin therapy compared to placebo, will improve β-cell
function, insulin sensitivity, and allow for a longer period of time prior to encountering an
insulin-deficient relapse after discontinuation of insulin therapy.